Go Pro
→ Larry's Three-Step Strategy Revealed at The Dollar Trap Summit (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.70
-3.1%		$0.73
$0.55
▼
$1.69
$8.83M1.66907,879 shs859,239 shs
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$0.07
+0.3%		$0.48
$0.07
▼
$4.29
$2.32M0.1917.36 million shs42.29 million shs
Immuron stock logo
IMRN
Immuron
$1.09
-3.5%		$1.21
$0.68
▼
$2.39
$8.80M1.09793,280 shs83,716 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$2.56
-1.3%		$6.12
$2.30
▼
$12.30
$8.17M-0.18224,213 shs14,153 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-3.53%-7.21%-13.43%-2.36%-50.45%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%0.00%-45.91%-94.63%-97.12%
Immuron stock logo
IMRN
Immuron
-2.59%-5.04%+5.61%+2.73%-40.84%
Longeveron Inc. stock logo
LGVN
Longeveron
-3.72%-11.00%-61.63%-62.49%-65.11%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.70
-3.1%		$0.73
$0.55
▼
$1.69
$8.83M1.66907,879 shs859,239 shs
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$0.07
+0.3%		$0.48
$0.07
▼
$4.29
$2.32M0.1917.36 million shs42.29 million shs
Immuron stock logo
IMRN
Immuron
$1.09
-3.5%		$1.21
$0.68
▼
$2.39
$8.80M1.09793,280 shs83,716 shs
Longeveron Inc. stock logo
LGVN
Longeveron
$2.56
-1.3%		$6.12
$2.30
▼
$12.30
$8.17M-0.18224,213 shs14,153 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-3.53%-7.21%-13.43%-2.36%-50.45%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
0.00%0.00%-45.91%-94.63%-97.12%
Immuron stock logo
IMRN
Immuron
-2.59%-5.04%+5.61%+2.73%-40.84%
Longeveron Inc. stock logo
LGVN
Longeveron
-3.72%-11.00%-61.63%-62.49%-65.11%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$3.07337.47% Upside
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
2.25
Hold$11.0014,744.80% Upside
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
2.00
Hold$80.003,028.67% Upside

Current Analyst Ratings Breakdown

Latest BTAI, APRE, IMRN, and LGVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/8/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$3.00
8/11/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/9/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K30.43N/AN/A$1.52 per share0.46
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
$640K3.63N/AN/A($4.37) per share-0.02
Immuron stock logo
IMRN
Immuron
$5.47M1.61N/AN/A$0.94 per share1.16
Longeveron Inc. stock logo
LGVN
Longeveron
$1.20M6.80N/AN/A$2.47 per share1.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.08N/AN/AN/AN/A-47.60%-40.97%11/11/2026 (Estimated)
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$69.90M-$3.79N/AN/AN/A-9,549.87%N/A-185.82%11/11/2026 (Estimated)
Immuron stock logo
IMRN
Immuron
-$2.50MN/AN/AN/AN/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
-$22.70M-$9.90N/AN/AN/A-1,977.59%-223.19%-150.20%11/3/2026 (Estimated)

Latest BTAI, APRE, IMRN, and LGVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q4 2026
Immuron stock logo
IMRN
Immuron
N/A-$0.08N/A-$0.0750N/A$1.27 million
8/13/2026Q2 2026
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
-$0.44-$0.49-$0.05-$0.49$0.49 million$0.18 million
8/12/2026Q2 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.1775-$0.07+$0.1075-$0.07$0.25 millionN/A
8/12/2026Q2 2026
Longeveron Inc. stock logo
LGVN
Longeveron
-$1.75-$0.19+$1.56-$1.90$0.33 million$0.29 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
13.56
13.56
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
N/A
0.21
0.21
Immuron stock logo
IMRN
Immuron
N/A
7.26
5.98
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
2.63
2.63

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
30.68%
Immuron stock logo
IMRN
Immuron
0.12%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
10.49%
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
3.70%
Immuron stock logo
IMRN
Immuron
7.01%
Longeveron Inc. stock logo
LGVN
Longeveron
7.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
812.59 million11.27 millionNo Data
BioXcel Therapeutics, Inc. stock logo
BTAI
BioXcel Therapeutics
9031.31 million30.15 millionNo Data
Immuron stock logo
IMRN
Immuron
78.07 million7.51 millionNot Optionable
Longeveron Inc. stock logo
LGVN
Longeveron
383.19 million2.95 millionNot Optionable

Recent News About These Companies

Longeveron average analyst price target decreased by 23.41% to $42.97
 |  msn.comhttps://www.msn.com/en-us/money/top-stocks/longeveron-average-analyst-price-target-decreased-by-23-41-to-42-97/ar-AA2dolkv
Financial Contrast: uniQure (NASDAQ:QURE) and Longeveron (NASDAQ:LGVN)
October 2 at 4:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077758
Comparing Longeveron (NASDAQ:LGVN) & ProQR Therapeutics (NASDAQ:PRQR)
October 1 at 3:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072979
Longeveron to Participate in Three Longevity/Aging Investment Conferences
September 30 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372378/0/en/longeveron-to-participate-in-three-longevity-aging-investment-conferences.html
Financial Contrast: Sera Prognostics (NASDAQ:SERA) and Longeveron (NASDAQ:LGVN)
September 30 at 4:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068138
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
September 22, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/news/longeveron-lgvn-heart-treatment-falls-short-can-a-strategic-review-preserve-value-1839291/
Longeveron Inc - Ordinary Shares - Class A
September 17, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/lgvn-longeveron-inc-ordinary-shares-class-a
LGVN Posts Disappointing Trial Results
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/lgvn-posts-disappointing-trial-results/ar-AA2cqY7i
Longeveron's Laromestrocel Misses Primary Endpoint In Phase 2b HLHS Trial; Stock Down 59%
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691680/longeveron-s-laromestrocel-misses-primary-endpoint-in-phase-2b-hlhs-trial-stock-down-59.aspx
Longeveron Shares Halted After Heart Therapy Trial Misses Primary Endpoint
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/longeveron-shares-halted-heart-therapy-220748271.html
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
September 16, 2026  |  reuters.comhttps://www.reuters.com/legal/litigation/longeveron-explores-strategic-options-after-therapy-fails-mid-stage-trial-infant-2026-09-16/
Longeveron Announces ELPIS II Results, Reviews Strategic Alternatives to Maximize Shareholder Value
September 16, 2026  |  quiverquant.comQ
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363591/0/en/longeveron-announces-topline-results-from-elpis-ii-phase-2b-clinical-trial-evaluating-laromestrocel-as-a-potential-treatment-for-hypoplastic-left-heart-syndrome-hlhs.html
Longeveron Regains Nasdaq Compliance With Minimum Bid Price
September 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longeveron-regains-nasdaq-compliance-with-minimum-bid-price?utm_source=marketbeat.com&utm_medium=referral
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355999/0/en/longeveron-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Longeveron Announces 1-for-10 Reverse Stock Split
August 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/24/3350096/0/en/longeveron-announces-1-for-10-reverse-stock-split.html
Longeveron Inc. Earnings Call: Trials, Cash and Risk
August 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/longeveron-inc-earnings-call-trials-cash-and-risk?utm_source=marketbeat.com&utm_medium=referral
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/longeveron-lgvn-q2-2026-earnings-215827971.html
Longeveron Inc. Appoints Nirav Jhaveri as Chief Financial Officer
August 19, 2026  |  quiverquant.comQ
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
August 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/19/3347971/0/en/longeveron-appoints-nirav-jhaveri-as-chief-financial-officer.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.70 -0.02 (-3.11%)
As of 03:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

BioXcel Therapeutics stock logo

BioXcel Therapeutics NASDAQ:BTAI

$0.07 +0.00 (+0.27%)
As of 09/4/2026
This is a fair market value price provided by Massive. Learn more.

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.09 -0.04 (-3.54%)
As of 03:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$2.56 -0.03 (-1.27%)
As of 03:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas